Substance Misuse To Psychiatric Disorders for Cannabis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2/PHASE3

Total Enrollment

37 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-07-25

Study Completion Date

2023-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

With the recent availability of vortioxetine, and the surging phenomenon of cannabis misuses amongst young abusers, it is a timely opportunity to conduct an early pharmacotherapy intervention study to offer an evidence-based strategy aiming to stop individuals with cannabis use disorders with depressive or anxiety symptoms, to develop into a more chronic disabling dependence or co-morbid state.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Treatment of Hypochondriasis With CBT and/or SSRI

NCT00339079

Hypochondriasis

COMPLETED PHASE1/PHASE2

Effects of Marijuana on Symptoms of OCD

NCT03274440

Obsessive-Compulsive Disorder

COMPLETED PHASE1/PHASE2

Epidiolex in Obsessive Compulsive Disorder and Related Disorders

NCT04978428

Obsessive-Compulsive Disorder Trichotillomania (Hair-Pulling Disorder) Tourette Syndrome +1 more

COMPLETED PHASE2

Vortioxetine for the Treatment of Hoarding Disorder

NCT04035850

Hoarding Disorder

WITHDRAWN PHASE3

Mechanisms of Treatment Change in Panic Disorder and Agoraphobia

NCT03547180

Panic Disorder With Agoraphobia

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cannabis Use Disorder Depressive State Anxiety State Depression Anxiety Disorders Pharmacotherapy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

prospective randomised single-blinded

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

treatment in each intervention arms is masked to the outcome assessor

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Vortioxetine Arm

Oral: 5-20mg daily

Group Type ACTIVE_COMPARATOR

Vortioxetine

Intervention Type DRUG

oral medication taken once daily

Treatment as Usual

Any medication or Rx other than vortixoetine

Group Type ACTIVE_COMPARATOR

Treatment as Usual

Intervention Type OTHER

Any pharmacological or non-pharmacotherapy modalities other than use of vortioxetine

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Vortioxetine

oral medication taken once daily

Intervention Type DRUG

Treatment as Usual

Any pharmacological or non-pharmacotherapy modalities other than use of vortioxetine

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

• Cannabis use disorder with anxiety or depressive symptoms or disorders; or positive cannabis test results in 1 month with anxiety or depressive symptoms

Exclusion Criteria

* Age \<16 years old
* Unable to read English or Chinese
* Unable to give informed consent
* Had been diagnosed to have Intellectual Disabilities (DSM-5) or Mental Retardation
* Had history of primary psychotic episode
* Had been diagnosed to have substance-induced mood disorder, other than cannabis
* Had been diagnosed to have mood disorders or anxiety disorders
* Had been taking maintenance therapeutic dose of antidepressant continuously \>= 6 months AND with depressive symptom or anxiety symptom being in remission
* Had known hypersensitivity to vortioxetine
* Had known history of serotonin syndrome
* Pregnant
* Mother currently breast-feeding
* Currently taking warfarin and/or having poorly controlled bleeding disorder
* Had history of prolonged QTc ≥500ms and/or known unstable or untreated cardiology disease

Minimum Eligible Age

16 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No